Quarterly Updates24 Jan 2026, 01:10 pm
OneSource Specialty Pharma: Q3FY26 Results; Transitional Quarter with $2,903 Million Revenue
AI Summary
OneSource Specialty Pharma Limited announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26). The company's revenue was $2,903 million, down 26% YoY, impacted by delayed semaglutide approvals in Canada. EBITDA stood at $173 million, down 88% YoY. Adjusted PAT was $(472) million with adjusted EPS of (24.1). The company reaffirmed its FY28 guidance with $400 million in organic revenue and $500 million including recently proposed acquisitions, subject to shareholder approvals.
Key Highlights
- Revenues at $2,903 million, down 26% YoY
- EBITDA at $173 million, down 88% YoY
- Adjusted PAT at $(472) million with adjusted EPS of (24.1)
- Effective interest rate (EIR) below 9%, 200bps lower YoY
- FY28 Guidance Reaffirmation: $400 million in organic revenue and $500 million including recently proposed acquisitions